Back to Screener

OmniAb, Inc. Warrant (OABIW)

Price$0.10

Favorite Metrics

Price vs S&P 500 (4W)-1.45%

All Metrics

Price vs S&P 500 (YTD)-18.63%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.01M
52-Week High$0.37
13-Week Price Return-66.03%
3-Month Return Std Dev317.37%
Year-to-Date Return-17.85%
5-Day Price Return0.51%
Month-to-Date Return23.13%
Price vs S&P 500 (13W)-64.33%
Beta1.56x
52-Week Low$0.08

Industry Peers — R&D — Physical Sciences(10)

SymbolP/E Ratio (Annual)ROE (TTM)Revenue Growth (5Y)Indicated Dividend Yield (Annual)Price
OABIWOmniAb, Inc. Warrant
$0.10
IQVIQVIA Holdings Inc.
22.22x22.28%7.50%$171.95
INCYIncyte Genomics Inc
14.67x29.15%14.03%$95.32
MEDPMedpace Holdings, Inc. Common Stock
32.83x118.82%22.27%$515.65
CRLCharles River Laboratories International, Inc.
-4.40%6.55%$176.94
ABSIAbsci Corporation Common Stock
-59.68%-10.14%$3.23
NRCNational Research Corporation Common Stock (Delaware)
34.98x58.51%0.61%3.59%$17.62
OABIOmniAb, Inc. Common Stock
-23.99%-4.31%$1.56
MXCTMaxCyte, Inc. Common Stock
-24.06%4.76%$0.82
NOTVInotiv, Inc. Common Stock
-50.77%53.35%$0.30
ISPCiSpecimen Inc. Common Stock
-496.37%-25.09%$0.12

About

OmniAb Inc develops proprietary antibody discovery technologies utilizing genetically engineered transgenic animals—OmniRat, OmniMouse, and OmniChicken—that produce fully human therapeutic antibodies optimized through in vivo affinity maturation. The company's platform enables rapid and efficient discovery of high-quality antibodies across diverse disease indications. By reducing development timelines while enhancing therapeutic quality, OmniAb accelerates the path from discovery to clinical application.